BR112013031928A2 - derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas de receptor de mglu2 - Google Patents

derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas de receptor de mglu2

Info

Publication number
BR112013031928A2
BR112013031928A2 BR112013031928A BR112013031928A BR112013031928A2 BR 112013031928 A2 BR112013031928 A2 BR 112013031928A2 BR 112013031928 A BR112013031928 A BR 112013031928A BR 112013031928 A BR112013031928 A BR 112013031928A BR 112013031928 A2 BR112013031928 A2 BR 112013031928A2
Authority
BR
Brazil
Prior art keywords
bicyclo
hexane
dicarboxylic acid
acid derivatives
receptor agonists
Prior art date
Application number
BR112013031928A
Other languages
English (en)
Other versions
BR112013031928B1 (pt
Inventor
Carlos Montero Salgado
David Edward Tupper
James Allen Monn
Lesley Walton
Lourdes Prieto
Teresa Tse Ki Man
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112013031928A2 publication Critical patent/BR112013031928A2/pt
Publication of BR112013031928B1 publication Critical patent/BR112013031928B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas de receptor de mglu2". a presente invenção fornece novos agonistas de mglu2 úteis no tratamento de distúrbio bipolar, esquizofrenia, e distúrbio de ansiedade generalizado. 19999687v1
BR112013031928-3A 2011-06-17 2012-06-07 Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico, seu uso, e composição farmacêutica BR112013031928B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11382208 2011-06-17
EP11382208.4 2011-06-17
US201161522791P 2011-08-12 2011-08-12
US61/522,791 2011-08-12
PCT/US2012/041229 WO2012173850A1 (en) 2011-06-17 2012-06-07 Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as mglu2 receptor agonist

Publications (2)

Publication Number Publication Date
BR112013031928A2 true BR112013031928A2 (pt) 2016-12-13
BR112013031928B1 BR112013031928B1 (pt) 2022-05-24

Family

ID=47357416

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031928-3A BR112013031928B1 (pt) 2011-06-17 2012-06-07 Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico, seu uso, e composição farmacêutica

Country Status (20)

Country Link
US (1) US9296710B2 (pt)
EP (1) EP2721012B1 (pt)
JP (1) JP5945592B2 (pt)
KR (1) KR101598679B1 (pt)
CN (1) CN103596933B (pt)
AU (1) AU2012271024B2 (pt)
BR (1) BR112013031928B1 (pt)
CA (1) CA2836485C (pt)
CY (1) CY1117682T1 (pt)
DK (1) DK2721012T3 (pt)
EA (1) EA023553B1 (pt)
ES (1) ES2587204T3 (pt)
HR (1) HRP20160676T1 (pt)
HU (1) HUE030171T2 (pt)
MX (1) MX2013014802A (pt)
PL (1) PL2721012T3 (pt)
PT (1) PT2721012T (pt)
RS (1) RS54888B1 (pt)
SI (1) SI2721012T1 (pt)
WO (1) WO2012173850A1 (pt)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006127A1 (en) 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
US5576323A (en) 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5849525A (en) 1994-03-09 1998-12-15 Brigham And Women's Hospital, Inc. Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same
GB9605429D0 (en) 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
EA001617B1 (ru) 1995-11-16 2001-06-25 Эли Лилли Энд Компани Антагонисты рецепторов возбудительной аминокислоты
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
KR100446892B1 (ko) 1998-01-28 2004-09-04 다이쇼 세이야꾸 가부시끼가이샤 함불소 아미노산 유도체
DE69918136T2 (de) 1998-08-31 2005-07-07 Taisho Pharmaceutical Co., Ltd. 6-Fluorobicyclo[3.1.0]Hexan-Derivate
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2002000605A1 (fr) 2000-06-28 2002-01-03 Taisho Pharmaceutical Co., Ltd. Nouveaux derives d'acide dicarboxylique
US7038077B2 (en) 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids
NZ526050A (en) 2001-01-11 2005-03-24 Lilly Co Eli Prodrugs of excitatory amino acids
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
US7067507B2 (en) 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
RU2315622C2 (ru) 2001-12-27 2008-01-27 Тайсо Фармасьютикал Ко.,Лтд. Производные 6-фторбицикло[3.1.0]гексана
AU2003218063A1 (en) 2002-04-03 2003-10-20 Eli Lilly And Company Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
US20050192273A1 (en) 2002-04-03 2005-09-01 Johnson Bryan G. Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
CN101362793A (zh) * 2002-06-11 2009-02-11 伊莱利利公司 兴奋性氨基酸前药
PT1517915E (pt) * 2002-06-11 2009-04-09 Lilly Co Eli Pró-drogas de amino ácidos de excitação
ES2355144T3 (es) * 2003-06-26 2011-03-23 Taisho Pharmaceutical Co., Ltd. Derivado de éster 2-aminobiciclo 3.1.0 hexano-2,6-dicarboxílico.
JP4984529B2 (ja) * 2003-06-26 2012-07-25 大正製薬株式会社 ２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体
DK2513085T3 (en) * 2009-11-18 2016-12-05 Suven Life Sciences Ltd Alfa4beta2 bicyclic compounds as nicotinic acetylcholine receptor ligands
AR079343A1 (es) 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

Also Published As

Publication number Publication date
CN103596933B (zh) 2016-03-23
RS54888B1 (sr) 2016-10-31
US20140113944A1 (en) 2014-04-24
PT2721012T (pt) 2016-07-27
HUE030171T2 (en) 2017-05-29
SI2721012T1 (sl) 2016-08-31
JP5945592B2 (ja) 2016-07-05
JP2014517035A (ja) 2014-07-17
EA201391700A1 (ru) 2014-04-30
EP2721012A1 (en) 2014-04-23
CY1117682T1 (el) 2017-05-17
CN103596933A (zh) 2014-02-19
HRP20160676T1 (hr) 2016-07-15
DK2721012T3 (en) 2016-08-15
CA2836485A1 (en) 2012-12-20
EA023553B1 (ru) 2016-06-30
AU2012271024A1 (en) 2013-11-21
WO2012173850A1 (en) 2012-12-20
AU2012271024B2 (en) 2015-07-09
PL2721012T3 (pl) 2017-05-31
US9296710B2 (en) 2016-03-29
EP2721012B1 (en) 2016-05-25
BR112013031928B1 (pt) 2022-05-24
KR101598679B1 (ko) 2016-02-29
ES2587204T3 (es) 2016-10-21
CA2836485C (en) 2016-12-13
MX2013014802A (es) 2014-01-24
KR20140009568A (ko) 2014-01-22

Similar Documents

Publication Publication Date Title
BR112014029454A2 (pt) síntese de pirrolo [2,3-b] piridinas
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
NZ702663A (en) Nuclear transport modulators and uses thereof
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
ECSP12011989A (es) Agonistas de mglu2
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
IN2014MN01892A (pt)
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
DOP2013000305A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
BR112013031928A2 (pt) derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas de receptor de mglu2
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
CU20140058A7 (es) Nuevos 2h-indizoles como antagonistas del receptor ep-2
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
BR112015001515A2 (pt) compostos terapêuticos
UA82244U (ru) Способ получения вещества с потенциальными физиологическими свойствами -1-(1',1'-дифтор-2'-бром-2'-хлорэтил)-бензимидазол
UY33560A (es) Compuestos heterociclicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/06/2012, OBSERVADAS AS CONDICOES LEGAIS